Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?

被引：1
|
作者：
Park, Jihye [1 ,2 ]
机构：
[1] Yonsei Univ, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Inst Gastroenterol, Coll Med, Seoul, South Korea
来源：
INTESTINAL RESEARCH | 2022年 / 20卷 / 01期
关键词：
NECROSIS FACTOR THERAPY; CROHNS-DISEASE; RISK-FACTORS; SURGERY; VEDOLIZUMAB;
D O I：
10.5217/ir.2021.00170
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [41] Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents
    Papaefthymiou, Apostolis
    Potamianos, Spyros
    Goulas, Antonis
    Doulberis, Michael
    Kountouras, Jannis
    Polyzos, Stergios A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (05) : 852 - 862
  • [42] Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
    Song, Hyo Yeop
    Seo, Geom Seog
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (09): : 605 - 613
  • [43] Obesity Does Not Impact Perioperative or Postoperative Outcomes in Patients with Inflammatory Bowel Disease
    Guardado, Jesse
    Carchman, Evie
    Danicic, Ashley E.
    Salgado, Javier
    Watson, Andrew R.
    Celebrezze, James P.
    Medich, David S.
    Holder-Murray, Jennifer
    JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 20 (04) : 725 - 733
  • [44] Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis
    Mevius, Antje
    Brandes, Alina
    Hardtstock, Fraence
    Wilke, Thomas
    Ratsch, Boris A.
    Orzechowski, Hans-Dieter
    Fuchs, Andreas
    Deiters, Barthold
    Bokemeyer, Bernd
    DIGESTION, 2021, 102 (02) : 216 - 226
  • [45] Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
    Barberio, Brigida
    Savarino, Edoardo Vincenzo
    Card, Timothy
    Canova, Cristina
    Baldisser, Francesco
    Gubbiotti, Alessandro
    Massimi, Davide
    Ghisa, Matteo
    Zingone, Fabiana
    INTESTINAL RESEARCH, 2022, 20 (01) : 114 - +
  • [46] Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients
    Anas Alsaleh
    Jill K. J. Gaidos
    Le Kang
    John F. Kuemmerle
    Digestive Diseases and Sciences, 2016, 61 : 2602 - 2607
  • [47] Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
    Alameddine, Zakaria
    Melhem, Racha Abi
    Dimachkie, Reem
    Rabah, Hussein
    Chehab, Hamed
    El Khoury, Michel
    Qaqish, Faris
    Stefanov, Dimitre
    El-Sayegh, Suzanne
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [48] The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial
    Papaefthymiou, Apostolis
    Sarrou, Styliani
    Pateras, Konstantinos
    Vachliotis, Ilias D.
    Agrotis, Georgios
    Sgantzou, Ioanna-Konstantina
    Perifanos, Georgios
    Kapsoritakis, Andreas
    Speletas, Matthaios
    Vlychou, Marianna
    Dalekos, George N.
    Potamianos, Spyros
    Goulas, Antonis
    Kountouras, Jannis
    Polyzos, Stergios A.
    PHARMACEUTICALS, 2024, 17 (11)
  • [49] Designing biologic selectivity for inflammatory bowel disease - role of vedolizumab
    Krupka, Niklas
    Baumgart, Daniel C.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 9 : 147 - 154
  • [50] Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights
    Chen, Wenshuo
    Chen, Haijin
    Fu, Shudan
    Lin, Xiaohua
    Zheng, Zheng
    Zhang, Jinlong
    BIOPROCESS AND BIOSYSTEMS ENGINEERING, 2021, 44 (05) : 929 - 939
12345